Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide DDI with CYP1A2 and CYP2D6 substrates in prostate cancer
NCT02225093Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2013
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by Astellas Pharma. Primary endpoints: Maximum concentration at Day 53, Area under the curve from time 0 to last measurable concentration at Day 53 and 1 more. Started Oct 2013; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02225093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02225093.